Hikma enters French generic injectables market

Hikma is expanding in Europe with the establishment of Hikma France S.A.S., to be known as Hikma France.

This marks Hikma’s official entry into France, which has the second largest pharmaceutical market in Europe and a generic injectables hospital market of approximately $2 billion, according to the company.

To date, Hikma has supplied 21 generic injectable medicines to hospitals in France through a third party.

[Read more: Hikma intros Kloxxado]

Following the approval of Hikma France and the opening of a new commercial office outside Paris, it will now supply medicines to hospitals directly. This broadened portfolio will span several therapeutic areas, including anti-infective, cardiovascular and central nervous system.

Hikma has an established and growing presence in Europe, with high-quality manufacturing plants in Portugal, Italy and Germany, supplying injectable products to North America, the Middle East, North Africa and Europe.

[Read more: Hikma to acquire Canadian assets of Teligent] 

“The expansion into France is an important step forward in our European growth ambition. Hikma France will complement our existing presence in Europe,” Riad Mishlawi, president of Hikma Injectables said. “I am excited by the opportunity to supply French hospitals and their patients with high quality and affordable injectable medicines. We look forward to building our presence here as we aim to become a key player in the French hospital market.”